Table II.
Associations between JCV viruria and selected baseline laboratory and demographic variables; JCV seropositive patients only
| Shedding (n = 32) No. (%) | No Shedding (n = 46) No. (%) | OR (95% CI) | |
|---|---|---|---|
| CD4 (cells/mm3) † | |||
| HIV-positive patients only | |||
| ≤200 | 2 (66.7) | 1 (33.3) | 2.5 (0.2 – 30.3) |
| 200–500 | 3 (30.0) | 7 (70.0) | 0.5 (0.1 – 2.4) |
| ≥500 | 13 (44.8) | 16 (55.2) | 1 (Ref.) |
| CDS (cells/mm3) † | |||
| HIV-positive patients only | |||
| < 500 | 7 (63.6) | 4 (36.4) | 3.2 (0.76 – 13.3) |
| ≥500 | 11 (35.5) | 20 (64.5) | 1 (Ref.) |
| CD4/CD8 ratio † | |||
| HIV-positive patients only | |||
| <1.5 | 11 (61.1) | 22 (91.7) | 0.1 (0.28 – 0.81)** |
| ≥1.5 | 7 (38.9) | 2 (8.3) | 1 (Ref.) |
| Rate of CD4 decline (cells/mm3 per year) † | |||
| HIV-positive patients only | |||
| ≤ − 50 | 10 (55.6) | 11 (55.0) | 1.0 (0.28 – 3.7) |
| >−50 | 8 (44.4)) | 9 (45.0) | 1 (Ref.) |
| IgGO.D. ‡ | |||
| < 1.0 | 6 (18.7) | 24 (52.2) | 1 (Ref.) |
| ≥ 1.0 | 26 (81.3) | 22 (47.8) | 4.7 (1.6 – 13.6)*** |
| BKV Viruria | |||
| No viruria | 31 (96.9) | 41 (89.1) | 1 (Ref.) |
| Viruria | 1 (3.1) | 5 (10.9) | 0.3 (0.03 – 2.4) |
| Age | |||
| ≤30 | 9 (28.1) | 13 (20.3) | 1 (Ref.) |
| 30–40 | 14 (43.8) | 20 (46.5) | 1.01 (0.3 – 3.0) |
| ≥40 | 9 (28.1) | 20 (23.3) | 1.30 (0.4 – 4.5) |
| Smoke | |||
| No | 19 (59.4) | 29 (60.4) | 1 (Ref.) |
| Yes | 12 (37.5) | 17 (36.9) | 1.1 (0.4 – 2.8) |
| Education | |||
| Less than College | 3 (9.4) | 2 (4.6) | 1 (Ref.) |
| college | 16 (50.0) | 26 (60.5) | 0.57 (0.10 – 3.17) |
| Post-college | 13 (40.6) | 15 (34.9) | 0.87 (0.14 – 5.06) |
| Steroid Use * | |||
| No | 28 (87.5) | 35 (76.1) | 1 (Ref.) |
| Yes | 4 (12.5) | 11 (23.9) | 0.5 (0.1 – 1.6) |
†
Analysis restricted to HIV-positive patients (patients with JCV Viruria (n = 18), patients without JCV Viruria (n = 24))
‡
Anti-JCV IgG optical density from visit 1 only
*
Steroid use includes use of oral, applied, or injected steroids
**
p < .05
***
p < .0001